Effects of Coexistent BRAF V600E and TERT Promoter Mutations on Poor Clinical Outcomes in Papillary Thyroid Cancer: A Meta-Analysis
Thyroid2017Vol. 27(5), pp. 651–660
Citations Over TimeTop 10% of 2017 papers
Shinje Moon, Young Shin Song, Ye An Kim, Jung‐Ah Lim, Sun Wook Cho, Jae Hoon Moon, Seokyung Hahn, Do Joon Park, Young Joo Park
Abstract
Coexistent BRAFV600E and TERT promoter mutations have a synergistic effect on clinical outcomes in PTC, whereas each mutation alone has a modest effect. Therefore, molecular testing of BRAFV600E and TERT promoter mutations together is useful in assessing risk stratification of PTC.
Related Papers
- → Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013(2017)2,149 cited
- → Thyroid Cancer Screening in South Korea Increases Detection of Papillary Cancers with No Impact on Other Subtypes or Thyroid Cancer Mortality(2016)213 cited
- → Lessons from Mouse Models of Thyroid Cancer(2009)52 cited
- → CDK12 promotes papillary thyroid cancer progression through regulating the c-myc/β-catenin pathway(2020)20 cited
- → Ultrasonographic prediction of highly aggressive telomerase reverse transcriptase (TERT) promoter-mutated papillary thyroid cancer(2017)20 cited